Potential conflict of interest: Nothing to report.
Donor PNPLA3 rs738409 genotype affects fibrosis progression in liver transplantation for hepatitis C
Article first published online: 23 DEC 2013
© 2013 by the American Association for the Study of Liver Diseases
Volume 59, Issue 2, pages 453–460, February 2014
How to Cite
Dunn, W., O'Neil, M., Zhao, J., Wu, C. H., Roberts, B., Chakraborty, S., Sherman, C., Weaver, B., Taylor, R., Olson, J., Olyaee, M., Gilroy, R., Schmitt, T., Wan, Y.-J. Y. and Weinman, S. A. (2014), Donor PNPLA3 rs738409 genotype affects fibrosis progression in liver transplantation for hepatitis C. Hepatology, 59: 453–460. doi: 10.1002/hep.26758
Supported by the American Association for the Study of Liver Diseases Sheila Sherlock Clinical and Translational Research Award 2012-2014, and University of Kansas Liver Center Pilot Project Award to W.D.
- Issue published online: 29 JAN 2014
- Article first published online: 23 DEC 2013
- Accepted manuscript online: 1 OCT 2013 06:55AM EST
- Manuscript Accepted: 17 SEP 2013
- Manuscript Revised: 12 AUG 2013
- Manuscript Received: 2 OCT 2012
The rs738409 G>C single nucleotide polymorphism occurring in the patatin-like phospholipase 3 gene has been identified as a novel genetic marker for hepatic steatosis. Recent studies also associated rs738409 with fibrosis in hepatitis C (HCV). Therefore, we sought to determine the impact of donor and recipient rs738409 genotype on the progression of fibrosis after liver transplantation for HCV. This cohort study included 101 patients infected with HCV who underwent liver transplantation between January 2008, and June 2011. Donor and recipient rs738409 genotypes were determined from donor wedge biopsies and recipient explants. The time to Ishak stage 3 fibrosis, or HCV-related mortality/graft loss was analyzed by the Cox model adjusting for HCV-Donor Risk Index, warm ischemic time, pretransplant Model for Endstage Liver Disease (MELD) and viral load. The rs738409 CC variant was present in 56% of donors and 57% of recipients. The median follow-up period was 620 days. A total of 39 patients developed the primary outcome of ≥stage 3 fibrosis or HCV-related mortality/graft loss, the time to which differed by donor (P = 0.019) but not recipient (P = 0.89) genotype. In the multivariate model, donor GC or GG variants had 2.53 times the risk (95% confidence interval [CI] 1.25-5.02, P = 0.008) compared to CC variants. In the alternative endpoint: stage 3 fibrosis or all-cause mortality/graft loss, the effect of donor genotype was attenuated but remained significant at 1.98 (95% CI 1.11-3.53). Conclusions: The rs738409 genotype is an important predictor of posttransplant outcome in HCV. Liver, and not adipocytes, is the site at which this effect occurs. Our finding may be useful in donor selection for liver transplantation with HCV, and may guide decisions regarding early antiviral treatment. (Hepatology 2014;59:453–460)